meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - maintenance (M)
2
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)
All treatments
endocrine therapy
androgen deprivation therapy (ADT)
abiraterone plus ADT
abiraterone plus docetaxel plus ADT
apalutamide plus ADT
darolutamide plus doxetaxel plus ADT
docetaxel plus ADT
enzalutamide
enzalutamide plus ADT
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
anti-PD-(L)1
pembrolizumab based treatment
versus all
vs chemotherapy
vs endocrine therapy
vs androgen deprivation therapy (ADT)
vs docetaxel plus ADT
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
summary
GRADE
treatment
patients
risk of bias
overview
numeric
bar chart
forest plot
medians
frequency on treatment
benefit risk analysis
Study
study type
RCT
OBS
RCT + OBS
Pathology
T1
T0
Patients
sample sizes
ROB
Results
deaths (OS)
E
progression or deaths (PFS)
E
RFS/DFS
E
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open